Pfizer recently announced results from a clinical study which is currently evaluating HYMPAVZI™ (marstacimab-hncq) for adults and adolescents living with hemophilia A or B with inhibitors. The therapy was approved by the U.S.

Summer is now in full swing, with the sunny promise of more opportunities to get outside and be active. With that in mind, the Neil Frick Resource Center (NFRC) is highlighting resources to encourage better joint health in people with hemophilia and other bleeding disorders. This edition references a series of multi-formatted resources, including articles, videos, educational publications, and medical recommendations. 

NBDF is delighted to share our latest Collaborative Learning Exchange (CLE), “Assessing the Wellbeing of Women with Bleeding Disorders: Focus on Bone and Mental Health.” Recorded live and virtually on June 25^th, the activity featured illustrative case studies, presentations, and thoughtful discussions about the critical need for regular screening for anxiety/depression and bone health in women with inherited bleeding disorders.

The National Bleeding Disorders Foundation was saddened to learn of the passing of Carol Kasper, MD, a pioneer in the treatment of bleeding disorders, who died on July 8, 2025.